Hazan J; Liu KY; Howard R. Clarity AD open-label extension data do not robustly confirm disease course modification by lecanemab in ApoE4 heterozygotes and non-carriers. # TJPAD-D-26-00165
Lutz Froelich · 2026
Read Hazan J; Liu KY; Howard R. Clarity AD open-label extension data do not robustly confirm disease course modification by lecanemab in ApoE4 heterozygotes and non-carriers. # TJPAD-D-26-00165 by Lutz Froelich (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13157039.txt.
Description
Lutz Froelich replies to peers on add-on data for a mind drug trial in a 2026 letter to the press. Peers had doubted if the long add-on run backs a true ill-slow claim for the drug in care. His first paper gave cure and safe marks in a gene-split sub-herd of the trial at hand.
That split was not set ahead but asked by rule groups in their file for the drug. Full-run and add-on data both sit in the tale the reply walks through for the peers. Marks show less rate loss on the drug in that herd in the end.
Catalog record
| CREATOR | Lutz Froelich |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 5 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |